GlassScriptPhysician profile
Jacob Michael Stephens
NPI 1700375136
$845.54
in general payments reported to CMS, 2019-2025
19 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $298 · 2022: $110 · 2023: $88.64 · 2024: $118 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359 · Consulting Fee: $60.00 · Gift: $18.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.22 |
| Consulting Fee | $60.00 |
| Gift | $18.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $184.96 | 2022-2025 | Vyepti |
| Amgen INC. | $140.47 | 2021-2025 | Evenity, Prolia, Prolia |
| Pharmacosmos Therapeutics INC. | $66.42 | 2021-2022 | |
| Biogen, INC. | $60.00 | 2025 | Tysabri |
| Novo Nordisk INC | $45.24 | 2021 | |
| Abiomed | $41.57 | 2024-2025 | Impella |
| Genentech USA, INC. | $36.88 | 2021-2025 | Ocrevus Zunovo |
| Takeda Pharmaceuticals U.S.A., INC. | $36.49 | 2021-2024 | Gammagard |
| Lilly USA, LLC | $32.48 | 2021 | |
| Alexion Pharmaceuticals, INC. | $28.12 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.36 | 2021-2023 | Spevigo |
| Janssen Biotech, INC. | $25.78 | 2025 | Tremfya |
| Glaxosmithkline, LLC. | $23.20 | 2021 | |
| Eisai INC. | $22.63 | 2023 | |
| Grifols USA, LLC | $16.51 | 2023 | Gamunex-C |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $15.96 | 2021 | |
| Daiichi Sankyo INC. | $15.67 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.87 | 2022 | |
| Philips North America LLC | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.